{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:42Z","timestamp":1787019582420,"version":"build-2736575974"},"reference-count":22,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapsed or refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge. Loncastuximab tesirine is an antibody-drug conjugate against CD19, an antigen expressed in many B-cell malignancies. This open-label, single-arm, dose-escalation, dose-expansion study assessed the safety, tolerability, pharmacokinetics (PKs), immunogenicity, and preliminary clinical activity of loncastuximab tesirine in adults with R\/R B-ALL. A total of 35 patients were enrolled, with a median age of 55 years (range, 20-80) and a median of 3 prior therapies (range, 1-15). All patients received at least 1 IV infusion of loncastuximab tesirine at 15 to 150 \u03bcg\/kg once every 3 weeks (Q3W; n = 30) or 50 \u03bcg\/kg IV weekly (n = 5). Common treatment-emergent adverse events (TEAEs) were nausea (42.9%), febrile neutropenia (37.1%), and reversible liver test abnormalities. Grade \u22653 TEAEs were reported in 85.7% patients, most commonly febrile neutropenia and other hematologic abnormalities and reversible liver test abnormalities. There were no treatment-related deaths. Four patients (11.4%) had grade 2 infusion-related reactions, and 1 patient (150 \u03bcg\/kg Q3W) had a dose-limiting toxicity of hyperbilirubinemia that resolved within 6 days without further action. The maximum tolerated dose was not reached. Three patients achieved complete responses, 1 each at 30, 120, and 150 \u03bcg\/kg Q3W. PK studies showed marked interpatient variability, with target-mediated drug disposition seeming to contribute to time- and dose-dependent disposition. No clinically relevant anti\u2013drug-antibody formation occurred. The trial was terminated in the dose-escalation phase because of slow accrual. This trial was registered at www.clinicaltrials.gov as NCT02669264.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000767","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T11:31:45Z","timestamp":1580729505000},"page":"449-457","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"4","author":[{"given":"Nitin","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"Duchossois Center for Advanced Medicine, The University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yale Cancer Center, New Haven, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[{"name":"Divison of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McCloskey","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Heffner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2014Hematology and Oncology, Seidman Cancer Center, Case Western Reserve University, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Feingold","sequence":"additional","affiliation":[{"name":"ADC Therapeutics America, Inc, Murray Hill, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ungar","sequence":"additional","affiliation":[{"name":"ADC Therapeutics America, Inc, Murray Hill, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chao","sequence":"additional","affiliation":[{"name":"ADC Therapeutics America, Inc, Murray Hill, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"ADC Therapeutics America, Inc, Murray Hill, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Qin","sequence":"additional","affiliation":[{"name":"ADC Therapeutics America, Inc, Murray Hill, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Havenith","sequence":"additional","affiliation":[{"name":"ADC Therapeutics (UK) Limited, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Wieduwilt","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"issue":"suppl 5","key":"2020021111261388300_B1","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"2020021111261388300_B2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica"},{"key":"2020021111261388300_B3","unstructured":"BLINCYTO prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125557s008lbl.pdf. Accessed 26 April 2019."},{"key":"2020021111261388300_B4","unstructured":"BESPONSA prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf. Accessed 26 April 2019."},{"key":"2020021111261388300_B5","unstructured":"Kymriah prescribing information. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM573941.pdf. Accessed 26 April 2019."},{"issue":"4","key":"2020021111261388300_B6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates--an emerging class of cancer treatment","volume":"114","author":"Diamantis","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"2020021111261388300_B7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"2020021111261388300_B8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3109\/10428194.2013.828354","article-title":"Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond","volume":"55","author":"Katz","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020021111261388300_B9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2020021111261388300_B10","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"2020021111261388300_B11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"2020021111261388300_B12","unstructured":"Study to evaluate the efficacy and safety of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma.\n          https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03589469. Accessed 18 March 2019."},{"key":"2020021111261388300_B13","unstructured":"Study of ADCT-402 in patients with relapsed or refractory B-cell lineage acute lymphoblastic leukemia (B-ALL). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02669264?cond=NCT02669264&rank=1. Accessed 19 March 2019."},{"key":"2020021111261388300_B14","unstructured":"National Comprehensive Cancer Network\n          . NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia (version 2). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed 29 May 2019."},{"issue":"18","key":"2020021111261388300_B15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2017-04-779389","article-title":"Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies","volume":"130","author":"Ryan","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020021111261388300_B16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2020021111261388300_B17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Invest New Drugs"},{"issue":"11","key":"2020021111261388300_B18","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-10-2056","article-title":"Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors","volume":"17","author":"Puzanov","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020021111261388300_B19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","article-title":"A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors","volume":"65","author":"Janjigian","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"S2","key":"2020021111261388300_B20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hon.60_2629","article-title":"Analysis of efficacy and safety of loncastuximab tesirine (ADCT-402) by demographic and clincial characteristics in relapsed\/refractory diffuse large B-cell lymphoma","volume":"37","author":"Radford","year":"2019","journal-title":"Hematol Oncol"},{"key":"2020021111261388300_B21","doi-asserted-by":"crossref","unstructured":"Radford\n              J\n            , KahlBS, HamadaniM, et al Interim results from the first-in-human clinical trial of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory diffuse large B-cell lymphoma [abstract]. Blood. 2018;132(suppl 1). Abstract 398.","DOI":"10.1182\/blood-2018-99-116081"},{"issue":"1","key":"2020021111261388300_B22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-018-0593-5","article-title":"CD19 CAR-T cell therapy for relapsed\/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies","volume":"11","author":"Zhang","year":"2018","journal-title":"J Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/449\/1634245\/advancesadv2019000767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/449\/1634245\/advancesadv2019000767.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T11:27:24Z","timestamp":1581420444000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/3\/449\/440984\/Loncastuximab-tesirine-an-antiCD19-antibodydrug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000767","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,3]]}}}